ZMB Member Jürgen Becker
ZMB Member
Jürgen Becker
Next ZMB-Member
Prof. Dr. Jürgen Becker
West German Cancer Center (WTZ)
Medical Faculty
University Duisburg-Essen
45141 Essen
- +49 201 183 6728
- Website
- Selected Publications
- Publication Metrics
-
- ZMB Research Program
Oncology
Research Overview
"It is the responsibility of those of us involved in today’s biomedical research enterprise to translate the remarkable scientific innovations we are witnessing into health gains for the nation." Elias A. Zerhouni, N Engl J Med 353; 15: 1621
Recent advances in cancer biology, molecular biology and immunology should allow for a significant impact on the treatment and management of cancer. Still, our knowledge of many fundamental aspects of biology in health and disease is insufficiently translated into the clinical situation to reliably improve cancer prevention and treatment; moreover, substantial parts of this knowledge were acquired by use of model systems, which are not always reflecting the clinical situation. Translational cancer research bridges the gap between laboratory-based science and patient care in the clinic and vice versa.
To this end, research in skin cancer permits to scrutinize tumor biology and cancer immunology with more ease than this is possible in other cancer entities: In skin, most tumors are diagnosed at early stages, are characterized by a progression in stages (i.e. loco-regional metastases preceding distant metastases), and the metastases are frequently localized in the skin. Thus, sequential tumor manifestations can be analyzed over the course of disease progression as well as during therapeutic interventions. These characteristics are extremely favorable for translational research strategies.

Selected Publications
-
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapyIn: Nature Communications Vol. 12 (2021) Nr. 1, pp. 346
ISSN: 2041-1723Online Full Text: dx.doi.org/ (Open Access) -
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED) : a randomised, double-blind, placebo-controlled, phase 2 trialIn: The Lancet Vol. 395 (2020) Nr. 10236, pp. 1558 - 1568
ISSN: 1474-547X; 0140-6736Online Full Text: dx.doi.org/ -
Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanomaIn: Annals of Oncology Vol. 31 (2020) Nr. 1, pp. 144 - 152
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ -
Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell CarcinomaIn: Clinical Cancer Research Vol. 26 (2020) Nr. 9, pp. 2257 - 2267
ISSN: 1078-0432; 1557-3265Online Full Text: dx.doi.org/ -
Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphomaIn: Blood Vol. 134 (2019) Nr. 13, pp. 1072 - 1083
ISSN: 1528-0020; 0006-4971Online Full Text: dx.doi.org/ -
HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapyIn: Cancer Research Vol. 79 (2019) Nr. 11, pp. 2947 - 2961
ISSN: 0008-5472; 0099-7013; 0099-7374; 1538-7445Online Full Text: dx.doi.org/ -
Circulating cell-free miR-375 as surrogate marker of tumor burden in Merkel cell carcinomaIn: Clinical Cancer Research Vol. 24 (2018) Nr. 23, pp. 5873 - 5882
ISSN: 1078-0432; 1557-3265Online Full Text: dx.doi.org/ -
Adjuvant treatment with pegylated interferon ?-2a versus low-dose interferon ?-2a in patients with high-risk melanoma : a randomized phase III DeCOG trialIn: Annals of Oncology Vol. 27 (2016) Nr. 8, pp. 1625 - 1632
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Evaluation of real world treatment outcomes in patients with metastatic merkel cell carcinoma (MCC) following second line chemotherapyIn: Annals of Oncology Vol. 27 (2016) Nr. Suppl. 6, pp. vi397
ISSN: 1569-8041; 0923-7534Online Full Text: dx.doi.org/ (Open Access) -
Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic LatencyIn: Cancer Research Vol. 76 (2016) Nr. 15, pp. 4347 - 4358
ISSN: 0008-5472; 1538-7445Online Full Text: dx.doi.org/ -
A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma : pretreatment impacts survivalIn: Annals of Oncology Vol. 26 (2015) Nr. 3, pp. 573 - 582
ISSN: 0923-7534; 1569-8041Online Full Text: dx.doi.org/ (Open Access) -
Neoadjuvant imatinib in advanced primary or locally recurrent dermatofibrosarcoma protuberans : A multicenter phase II DeCOG Trial with Long-Term Follow-UpIn: Clinical Cancer Research Vol. 20 (2014) Nr. 2, pp. 499 - 510
ISSN: 1557-3265; 1078-0432Online Full Text: dx.doi.org/ -
T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donorsIn: Clinical Cancer Research Vol. 20 (2014) Nr. 7, pp. 1768 - 1778
ISSN: 1557-3265; 1078-0432Online Full Text: dx.doi.org/ -
Improved survival with MEK inhibition in BRAF-mutated melanomaIn: The New England Journal of Medicine Vol. 367 (2012) Nr. 2, pp. 107 - 114
ISSN: 0028-4793; 1533-4406Online Full Text: dx.doi.org/